In the IMMUNED study,25 a phase II study of postoperative dual immunotherapy versus single anti‐PD1 and placebo in patients with stage IV melanoma, nivolumab (NIVO) + ipilimumab (IPI) adjuvant therapy was superior to NIVO in terms of RFS in patients with BRAF mutation subtypes. This evidence concerns the gene BRAF and melanoma.